COVID-19 Vaccine Regulatory Strategy Evolving With The Pandemic

AstraZeneca and Novavax have not filed EUAs for their vaccines, and they never might. The pathway remains viable in the short-term, but as BLAs are approved and supplies are no longer short, the window may close.

Vaccinating the globe against COVID-19
FDA emergency use authorization of the AstraZeneca and Novavax COVID-19 vaccines could be more beneficial for other countries than the US. • Source: Alamy

Reported decisions by AstraZeneca PLC and Novavax, Inc. to alter development and launch strategies for their coronavirus vaccines may not necessarily affect the US campaign against the virus, but could upset global efforts, as well as the US place in them.

With US vaccine supply now outpacing demand, the immediate domestic need for another product is waning. But the impact of...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Vaccines

More from Pink Sheet